Novo Nordisk cut its full-year guidance as U.S. sales continue to be hurt by copycat versions of its blockbuster Wegovy ...

Novo Nordisk A/S (NYSE:NVO) is one of the top low volatility healthcare stocks to buy now. In a report released on July 17, ...

The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.View ...

Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...

Novo Nordisk has lowered its full-year 2025 sales and operating profit forecasts due to weaker-than-expected growth in its ...

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO. Doustdar will succeed Lars Fruergaard Jørgensen, whose surprise abdication was ...

Novo Nordisk’s shares plunged more than a fifth on Tuesday, wiping more than €60bn from its value, after it slashed sales and profit forecasts for the year amid competition from US copycat weight-loss ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of ...

Novo Nordisk announces a leadership transition as Lars Fruergaard Jørgensen welcomes new CEO Doug Doustdar. Doustdar aims to ...

Novo Nordisk (NYSE:NVO) is one of the most profitable value stocks to buy according to analysts. On July 25, Novo Nordisk ...

Novo Nordisk stocks plunged by 7% in premarket trading following an announcement by the company that it has lowered its ...